# Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

> **NCT06196827** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Innostellar Biotherapeutics Co.,Ltd** · enrollment: 9 (actual)

## Conditions studied

- Inherited Retinal Dystrophy Associated With RPE65 Mutations

## Interventions

- **GENETIC:** LX101

## Key facts

- **NCT ID:** NCT06196827
- **Lead sponsor:** Innostellar Biotherapeutics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-02
- **Primary completion:** 2023-12-06
- **Final completion:** 2027-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196827, "Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06196827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*